What they were paid
Acrivon Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $52,500 | — | $17,870 | $0 | $70,370 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Acrivon Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-194206, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Acrivon Therapeutics pays directors a $40,000 cash retainer and $210,000 in Options.
Committees
FY2025 · as the proxy prints themAudit · Nominating/Governance
The rest of the Acrivon Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Charles Baum, M.D., Ph.D | Independent Director | $77,870 |
| Ivana Magovčević-Liebisch, Ph.D., J.D | Independent Director | $65,370 |
| Kristina Masson, Ph.D., M.B.A | Director | $0 |
| Michael Tomsicek, M.B.A | Independent Director | $72,870 |
| Peter Blume-Jensen, M.D., Ph.D | Chair of the Board | $0 |
| Santhosh Palani, Ph.D., CFA | Independent Director | $118,308 |
| Sharon Shacham, Ph.D., M.B.A | Independent Director | $65,370 |
The full Acrivon Therapeutics compensation record
free company briefThis page is one director within Acrivon Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat